Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA
| Title: | Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA |
|---|---|
| Authors: | Heinke, AnnaAff1, Aff2, Aff3, IDs40942025006914_cor1; Warter, AlexandraAff1, Aff2; Nagel, Ines D.Aff1, Aff2, Aff5; Agnihotri, AkshayAff1, Aff2; Mehta, Nehal NaileshAff1, Aff2; Galang, Carlo Miguel B.Aff1, Aff2; Deussen, Daniel N.Aff1, Aff2, Aff4; Bartsch, Dirk-Uwe G.Aff1, Aff2; Cheng, LingyunAff1, Aff2; Ferreyra, Henry A.Aff2; Freeman, William R.Aff1, Aff2 |
| Source: | International Journal of Retina and Vitreous. 11(1) |
| Database: | Springer Nature Journals |